Pensionfund Sabic Has $2,502,000 Stake in Eli Lilly and Company (LLY)
Pensionfund Sabic held its position in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,400 shares of the company’s stock at the end of the 2nd quarter. Eli Lilly and accounts for 0.8% of Pensionfund Sabic’s portfolio, making the stock its 23rd biggest position. Pensionfund Sabic’s holdings in Eli Lilly and were worth $2,502,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Heritage Trust Co purchased a new stake in Eli Lilly and in the first quarter worth $135,000. Point72 Asia Hong Kong Ltd increased its stake in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares during the period. Penserra Capital Management LLC increased its stake in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares during the period. Sandy Spring Bank increased its stake in Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after purchasing an additional 750 shares during the period. Finally, Coldstream Capital Management Inc. purchased a new stake in Eli Lilly and in the first quarter worth $200,000. Institutional investors and hedge funds own 75.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Pensionfund Sabic Has $2,502,000 Stake in Eli Lilly and Company (LLY)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/12/pensionfund-sabic-has-2502000-stake-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company (NYSE:LLY) traded down 0.38% during midday trading on Tuesday, hitting $82.32. The company had a trading volume of 1,043,737 shares. The company has a market cap of $86.85 billion, a price-to-earnings ratio of 35.62 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The firm has a 50-day moving average price of $80.88 and a 200-day moving average price of $82.05.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the prior year, the firm earned $0.86 EPS. The business’s revenue was up 7.8% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were given a dividend of $0.52 per share. The ex-dividend date was Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. Eli Lilly and’s payout ratio is 90.04%.
A number of analysts have weighed in on LLY shares. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $92.00 target price on shares of Eli Lilly and in a research note on Tuesday, May 16th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a research note on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 target price (up previously from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research note on Tuesday, July 4th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average target price of $88.07.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 825,000 shares of company stock valued at $68,456,650 over the last ninety days. 0.20% of the stock is owned by insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.